Bio-Techne Corp
NASDAQ:TECH
Bio-Techne Corp
Cash from Operating Activities
Bio-Techne Corp
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Bio-Techne Corp
NASDAQ:TECH
|
Cash from Operating Activities
$264.9m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Cash from Operating Activities
$8.1B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
12%
|
CAGR 10-Years
12%
|
|
|
Danaher Corp
NYSE:DHR
|
Cash from Operating Activities
$6.2B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
9%
|
CAGR 10-Years
5%
|
|
|
Mettler-Toledo International Inc
NYSE:MTD
|
Cash from Operating Activities
$972.8m
|
CAGR 3-Years
5%
|
CAGR 5-Years
11%
|
CAGR 10-Years
8%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Cash from Operating Activities
$1.6B
|
CAGR 3-Years
6%
|
CAGR 5-Years
14%
|
CAGR 10-Years
3%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Cash from Operating Activities
$2.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
13%
|
CAGR 10-Years
21%
|
|
Bio-Techne Corp
Glance View
Bio-Techne Corp. began its journey with a clear focus: to bridge the gap between biological research and practical applications, a mission that it continues to pursue with zeal. At its core, Bio-Techne operates as a pioneer in the production and distribution of biotechnology products, catering to the needs of the scientific community across the globe. The company specializes in providing essential tools for life sciences research, including proteins, antibodies, and reagents, empowering researchers to explore and innovate in fields ranging from cancer biology to neuroscience. These offerings are developed with meticulous care and a deep understanding of the scientific process, which positions Bio-Techne as a trusted ally to laboratories and research institutions worldwide. The financial heartbeat of Bio-Techne lies in its diverse portfolio, which extends into clinical diagnostics and genomics, segments that are critical in an era of personalized medicine and rapid technological advancement in healthcare. The company's revenue streams are robust, driven by a strategic blend of direct sales and collaborations with major pharmaceutical and biotech companies. Furthermore, Bio-Techne smartly leverages its acquisitions to fortify its market position, enhancing its capabilities and expanding its product lines. This agility and foresight not only enable Bio-Techne to sustain its growth trajectory but also to continually meet the ever-evolving demands of a fast-paced, innovation-driven industry.
See Also
What is Bio-Techne Corp's Cash from Operating Activities?
Cash from Operating Activities
264.9m
USD
Based on the financial report for Mar 31, 2025, Bio-Techne Corp's Cash from Operating Activities amounts to 264.9m USD.
What is Bio-Techne Corp's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
7%
Over the last year, the Cash from Operating Activities growth was -14%. The average annual Cash from Operating Activities growth rates for Bio-Techne Corp have been -8% over the past three years , 4% over the past five years , and 7% over the past ten years .
You don't have any saved screeners yet